Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 5/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.37 |
| ▸ | PTGES | O14684 | 1/20 | 0.36 |
| ▸ | DCUN1D1 | Q96GG9 | 5/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | UBE2M | P61081 | 4/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19670554 | 0.90 | MGLL (0.40) | MGLLPTGESDCUN1D1UBE2MPOLB | |
| SCHEMBL19365557 | 0.80 | MGLL (0.40) | MGLLHDAC1HDAC2PTGESDCUN1D1 | |
| SCHEMBL19699106 | 0.77 | MGLL (0.43) | MGLLPTGESENPP2 | |
| SCHEMBL19706296 | 0.76 | POLB (0.39) | HDAC1DCUN1D1UBE2MMCHR1POLB | |
| SCHEMBL19670547 | 0.74 | MGLL (0.39) | MGLLPTGES | |
| SCHEMBL16249968 | 0.73 | MGLL (0.39) | MGLLPTGESDCUN1D1UBE2M | |
| SCHEMBL16785551 | 0.69 | HDAC1 (0.45) | MGLLHDAC1RAB9A | |
| SCHEMBL16775744 | 0.67 | ATM (0.43) | MGLL | |
| SCHEMBL19365784 | 0.65 | POLB (0.47) | DCUN1D1UBE2MMCHR1POLBRAB9A | |
| SCHEMBL19688778 | 0.63 | MGLL (0.76) | MGLLENPP2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2020-03-17 | — | — | US | disclosed |
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | MGLL 2998/4885HDAC1 71/4885HDAC2 50/4885 |
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | SIRT1, SIRT3, SIRT2 | MGLL 2998/4885HDAC1 71/4885HDAC2 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.